Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose-ranging study.

Abstract

OBJECTIVES:

To determine the progestational efficacy of continuous treatment with various doses of dienogest, combined with oestradiol valerate, on the basis of endometrial histology, effect on climacteric symptoms and bleeding profile in postmenopausal women.

METHODS:

Patients were randomised to one of five fixed-combination treatments, oestradiol valerate 2.0 mg plus dienogest 0.5, 1.0, 2.0, 3.0 or 4.0 mg. Efficacy was assessed by endometrial biopsy, menstrual charts and change in climacteric symptoms.

RESULTS:

The endometrium was classified as atrophic in 20.0, 31.3, 25.0, 55.6 and 57.1% of patients in the 0.5, 1.0, 2.0, 3.0 and 4.0 mg dienogest groups, respectively. The frequency of uterine bleeding was dose-dependent. The most favourable bleeding profile was seen in the 3.0 mg dienogest group, whereas the lower doses of dienogest had advantages with respect to the efficacy of the combined preparation.

CONCLUSIONS:

Dienogest 2.0 and 3.0 mg are the optimal doses for combination with 2.0 mg oestradiol valerate for continuous-combined hormone replacement therapy.

• Authors: T Gräser, A Müller, U Mellinger, A O Mück, T H Lippert, M Oettel
• Journal: Maturitas (Maturitas) Vol. 35 Issue 3 Pg. 253-61 (Jun 30 2000) ISSN: 0378-5122 [Print] Ireland
• PMID: 10936742 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Estrogens, Conjugated (USP)
• Progesterone Congeners
• dienogest
• Estradiol
• Nandrolone

Topics

• Adult
• Aged
• Dose-Response Relationship, Drug
• Drug Therapy, Combination
• Endometrium (drug effects, pathology)
• Estradiol (administration & dosage, analogs & derivatives, therapeutic use)
• Estrogens, Conjugated (USP) (administration & dosage, therapeutic use)
• Female
• Germany
• Hormone Replacement Therapy
• Humans
• Menopause
• Middle Aged
• Nandrolone (administration & dosage, analogs & derivatives, therapeutic use)
• Progesterone Congeners (administration & dosage, therapeutic use)